Loading...
Please wait, while we are loading the content...
Similar Documents
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Bidoli, Paolo Zilembo, Nicoletta Cortinovis, Diego Luigi Mariani, Luigi Isa, Luciano Aitini, Enrico Cullurà, Daniela Pari, Franca Nova, Paola Mancin, Maddalena Formisano, Barbara Bajetta, Emilio |
| Copyright Year | 2007 |
| Abstract | BACKGROUND Many patients with advanced non-small-cell lung cancer (NSCLC) do not tolerate cisplatin-based regimens because of its nonhemathological toxicity. PATIENTS AND METHODS We evaluated the response rate safety of new platinum analogue regimens, randomizing 147 patients with nonoperable IIIB/IV NSCLC to (i) carboplatin (area under the curve = 5 mg min/ml) on day 1 plus gemcitabine (GEM) (1000 mg/m(2)) on days 1 and 8 for six cycles; (ii) same regimen for three cycles followed by docetaxel (Taxotere) (40 mg/m(2)) on days 1 and 8 plus GEM (1250 mg/m(2)) on days 1 and 8 for three cycles; (iii) oxaliplatin (130 mg/m(2)) on day 1 plus GEM (1250 mg/m(2)) on days 1 and 8 for six cycles. RESULTS Intention-to-treat objective response rates were 25%, 25% and 30.6% in arms A, B and C, respectively. Median survival was 11.9, 9.2 and 11.3 months in arms A, B and C, respectively. Grade 3/4 neutropenia/anemia occurred in 29%/12.5%, 10%/16.5% and 8%/6% of arms A, B and C, respectively; grade 3/4 thrombocytopenia in 20.5%, 16.5% and 6%; grade 1/2 neurological toxicity in 43% of arm C. CONCLUSIONS Oxaliplatin/GEM (arm C) had similar activity to carboplatin/GEM (arm A), but milder hematological toxicity and may be worth testing in a phase III study against carboplatin/GEM in patients not suitable for cisplatin. The sequential regimen gave no additional benefit. |
| Starting Page | 5895 |
| Ending Page | 5919 |
| Page Count | 25 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/18/3/10.1093/annonc/mdl415/2/mdl415.pdf?Expires=1492480654&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q&Signature=hCgmZluj-Y6qD3xsZhyvpfJpwC67px-IcjmbjO1E7xtGcil0Uhqg0OxOiy3sGJ4OaYlFhSPmqJeaW6taaE4dy4cEglQJoDgFzGb~F6lKSethke-TB~MwZDFRU7ogQwTvEbLwi8RuZRXuZ55SWGY-h2cw4PETwuiqqaSTKb1mjTIpUoULNMHd7Mp6ElUUrKJ0s~wBzwaMH-4tLiE72mphbtfhCHKQHRpJuROGqP9eSM2qsXrnN8dD7YOckKaXfIOaDp0vDl-TUs8UGkyU2feOawxI1aLQb6uclfhW47bIpUKcQiO6CHbN5e006bDj5tHWPb35lyHlnjr8nbgX2dsuhA__ |
| Alternate Webpage(s) | https://watermark.silverchair.com/mdl415.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAaQwggGgBgkqhkiG9w0BBwagggGRMIIBjQIBADCCAYYGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMOxAxFOyURBhLVa0MAgEQgIIBV0N4IoGtQcbhNb7v9nTnojs0NjYfJJQwR5Wi5AgVMH7VY1FAMnMjYKWMhsZvbFf8QGcv7aQ5dYXirMvLWdoAFtwuztkHjC8Td44EE1FxXg52O1TP7cWDJVowXgkVe25puqN8YIxNOOt1n2aZV7CrWG-Qw92ff-zywHMKekjnP4pco5xsDAs-WrDdI2dmA-bSCOI9w3Z11_NuFippLoFErCBaVMt4-G52y4b0Lw-d9t4o0na70EiiO5GQOcD7CStOw4i7r-njvo-bqf3dAkG8D5KBOmNV_cYmef0OFhRXRMgZRW4vi4gFI95IyPd8oFTJr9Ie-2Q8bc0U3Uat7_gTJosg_cNRFW_WKLZz7t9uzpZt-cBlAGKB3X0W3b2GBiUA1RZYmeJqos7uiiwOwcPNfdI1IE-A-2_PkkgrqIlH5gk0FBpUgDRFmRV3rILHSgkfjQ1Do7tm4i8 |
| PubMed reference number | 17110590v1 |
| Volume Number | 18 |
| Issue Number | 3 |
| Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adverse reaction to drug Alveolar rhabdomyosarcoma Analog Anemia Area Under Curve Carboplatin Carcinoma of lung Cisplatin Hematological Disease Neutropenia Non-Small Cell Lung Carcinoma One Thousand Patients Platinum Taxotere Thrombocytopenia docetaxel gemcitabine oxaliplatin |
| Content Type | Text |
| Resource Type | Article |
